Press Releases
  Date Title View
Jan 21, 2015
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, January 30, 2015, to d...
PDF
Jan 11, 2015
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops targeted anticancer therapies using its antibody-drug conjugate (ADC) technology, today announced ImmunoGen expectations for its product pipeline in 2015 that Company management will be discussing at t...
PDF
Dec 22, 2014
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops targeted anticancer therapies using its antibody-drug conjugate (ADC) technology, today announced the appointment of Richard J. Gregory, Ph.D., as Executive Vice President, Research and Chief Scientifi...
PDF
Dec 19, 2014
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today reported that Roche has announced top-line results of its Phase III MARIANNE study. The ...
PDF
Dec 15, 2014
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that Daniel Junius, President and CEO, will present at the upcoming 33rd Annual J.P. Morgan Healthcare ...
PDF
Dec 6, 2014
IMGN529 achieved objective responses in four of ten (40%) evaluable patients with heavily pretreated diffuse large B-cell lymphoma (DLBCL) - including a complete response - at the dose levels evaluated to date. Dose finding is ongoing, with the maximum tolerated dose (MTD) not yet esta...
PDF
Nov 24, 2014
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced the data presentations on Company and partner experimental therapies to be made at the upcoming America...
PDF
Nov 13, 2014
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that it has been named one of The Boston Globe's Top Places to Work. The Company has received ...
PDF
Oct 24, 2014
− Conference Call Today at 8:00 am ET− Advancing pipeline of wholly owned therapeutic candidates: IMGN853 in initial evaluation of efficacy in treatment of targeted ovarian and endometrial cancers; new IMGN529 clinical data to be reported at ASH; dose-finding evaluati...
PDF
Oct 10, 2014
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, October 24, 2014, to d...
PDF
Sep 15, 2014
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (NASDAQ: IMGN), a biotechnology company that develops targeted anticancer therapies using its antibody-drug conjugate (ADC) technology, today announced the appointment of Sandra E. Poole as Senior Vice President, Technical Operations. Ms. Poole b...
PDF
Sep 2, 2014
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will participate in the Morgan Stanley Global Healthcare Conference. Consistent with t...
PDF
Aug 4, 2014
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the following presentation by Company management at an upcoming investor conference will be webcas...
PDF
Aug 1, 2014
−Company Provides Corporate Update and Fiscal Year 2015 Financial Guidance − − Conference Call Today at 8:00 am ET− Advancing pipeline of wholly owned therapeutic candidates: IMGN853 beginning evaluation in target patient populations; initial e...
PDF
Jul 18, 2014
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the Company will host a conference call at 8:00 a.m. ET on Friday, August 1, 2014, to discuss Immu...
PDF
Jun 16, 2014
Novel antibody-drug conjugate is designed to selectively target and kill CD33-expressing acute myeloid leukemia cells, including leukemic stem cells, while sparing normal cells. IMGN779 utilizes one of the Company's new DNA-acting payload agents, DGN462. ...
PDF
Jun 1, 2014
SAR3419 achieved objective responses well above the study threshold and was found to have a favorable safety profile. Objective responses reported in patients whose disease had not responded to prior therapy. Selected for Best of ASCO. ...
PDF
May 14, 2014
Abstracts made public today provide insight on biological effects seen at low doses with IMGN529 and on observed activity threshold for IMGN853. Abstracts also add to growing body of data on the significance of partner compounds, including the findings reported on the activity and ...
PDF
May 6, 2014
WALTHAM, Mass.--(BUSINESS WIRE)-- ImmunoGen, Inc. (Nasdaq: IMGN), a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company management at upcoming investor conferences will be webcast...
PDF
Apr 25, 2014
Wholly owned product candidates - advancing, with expanding news flow expected. Kadcyla® sales growing - launches in European Union starting. Beyond Kadcyla - encouraging initial clinical findings now reported with six other compounds in development ...
PDF
1
... NextLast

You are now leaving this website. If you would like to continue, click Continue.
CancelContinue